NuScale Power Corporation

Executive Summary

HOLD, High conviction. Rated HOLD, High conviction. NuScale has a real asset, the only SMR design certification management cited with NRC approval, plus an unusually strong balance sheet with $1.9B of liquidity and no debt, but the operating business is still near-zero revenue and management again provided no formal financial guidance. At $8.11, down 85.9% from the 52-week high, the setup is no longer euphoric, yet the quant target of $7.67, or -5.4%, still fits a base case where commercialization remains delayed into 2027.

Investment Thesis

NuScale sits in an unusual spot. It is not financially distressed, and it is not technologically empty. The company has $1.9B of liquidity, no debt, a supplier network of 60+ suppliers, long-lead forgings already underway for 2 years, and a fuel path using standard LEU rather than HALEU. For an advanced nuclear developer, that is real progress. If commercial contracts land, the equity has leverage because the stock is already down 85.9% from the high and the short base is massive.

What the market still does not have is proof that this readiness converts into revenue on a visible schedule. The latest quarter showed $0.1M of revenue, down from $8.1M a year earlier, and management offered no explicit financial guidance on revenue, OpEx, EBITDA, or timing of broader commercialization. That matters more than the narrative. A company with a $2.5B market cap and P/S of 128.96x needs a line of sight to sales. Right now investors have statements like "We expect commercialization to happen soon. And so we're preparing for it," but not a signed project economics package that supports earnings power.

The core case depends on three things. First, TVA or Romania must move from active discussion to definitive agreement. Second, NuScale must show that first projects can be financed and executed without destroying customer economics, which is the key issue for every nuclear entrant. Third, management needs to rebuild timing credibility after repeated earnings misses and visible schedule drift from the 2024 Q3 framing to today's 2027 revenue expectation for RoPower.

The reason this is not a SELL is the balance sheet and strategic option value. Many pre-revenue industrial technologies fail because they run out of money before demand arrives. NuScale does not have that problem today. The reason it is not a BUY is simpler: there is still no hard financial bridge from technical readiness to cash generation. At $8.11, the stock is closer to fair waiting value than to a clear bargain. Proof, not promise, is the missing ingredient.

Key Metrics

Financial Strength

The balance sheet is the clear strength here. NuScale has no debt, a 37.88 current ratio, and $1.9B of liquidity, which is exceptional relative to its current operating scale and gives it time to absorb negative FCF and continue design and supplier spending. The weak point is not solvency but conversion: margins remain deeply negative because revenue is still negligible, so the company is financially safe near term but not financially proven. This is a well-funded option on commercialization, not a self-funding industrial business.

Competitive Position

NuScale's moat is mostly regulatory and ecosystem-based, not financial. Management cited being the only SMR with NRC design certification, and that matters because licensing lead times, supplier qualification, and utility procurement cycles are long. The moat is durable only if it converts into signed deployments soon, because a paper advantage can erode if customers choose larger incumbents, state-backed reactors, or other firm-power solutions before NuScale reaches commercial scale.

Management & Guidance

Management's latest guidance was notable for what it did not include. The 2026 Q2 call provided no formal OpEx, revenue, EBITDA, or commercialization timing guidance, instead emphasizing readiness, liquidity, and supplier progress. The only timing markers with financial relevance were that RoPower revenue is expected in 2027 and pre-EPC timing to final notice to proceed is about 1 year from the call. Given the earnings history, including major misses in late 2025 and early 2026, that limited guidance should be treated cautiously until a definitive agreement is signed.

Segment Analysis

• Licensing and engineering services (Effectively all current revenue): Revenue is milestone-based and highly lumpy, with Q2 2026 at $0.1M versus $8.1M a year earlier after prior Fluor FEED Phase 2 work did not repeat
• U.S. opportunity set, including TVA/ENTRA1 (Pre-revenue): Management said talks are active, but there is no definitive PPA/FID yet and no revenue timing disclosed
• Romania, RoPower (Pre-revenue today): Management now points to revenue next year (2027), with pre-EPC timing to final notice to proceed of about 1 year from the Q2 call

Capital Allocation

Capital allocation is conservative and appropriate for the stage. There are no buybacks, no dividend, essentially no capex, and management has prioritized liquidity, building cash and investments to $1.9B from roughly $1.0B q/q. That discipline lowers financing risk, but it also underscores the current reality that nearly all value rests on future project conversion rather than returns on deployed capital today.

Management Execution & Track Record

Execution against the 2024 Q3 playbook has been mixed at best. In late 2024, management said the 77 MWe design approval remained on schedule for mid-2025, and positioned RoPower's FEED at 12 to 14 months with a final investment decision in about 1 year from then; by the 2026 Q2 call, the message had shifted to general readiness, with RoPower revenue next year, 2027 and pre-EPC timing to final notice to proceed of about 1 year from now, which implies slippage versus the earlier commercial tempo. The balance-sheet promise was delivered strongly, with cash and investments improving from $161.7M in 2024 Q3 to $1.9B at 2026 Q2 and debt still at $0.0B. But the commercial promises remain largely unproven: revenue was $0.5M in 2024 Q3, $0.1M in 2026 Q2, and the earnings record shows large misses, including -1225.0% on 2025-11-06 and -700.0% on 2026-02-26. Management looks credible on technical readiness and liquidity, less credible on timing.

Positioning & Flows

Ownership is unusually concentrated, with insiders at 84.4% and the top three institutions at 64.4%, which can amplify moves in both directions when news hits. Short interest is extreme, at 58.48% on one dataset and 76.1M shares on a 130M float in another, with 2.2 days-to-cover, so a signed project could squeeze hard, but absent that catalyst the short base reflects a rational challenge to valuation and timing. Options positioning is also fragile, with negative gamma and zero-gamma at $8.32, close to spot, which can reinforce volatility rather than stabilize it.

Bull Case

• $1.9B liquidity versus $0.0B debt gives NuScale time to fund engineering, supplier readiness, and commercialization without immediate balance-sheet stress
• Technology and regulatory progress are tangible: management said NuScale is the only SMR with NRC design certification, long-lead forgings at Doosan have been underway for 2 years, and the Paragon I&C final design contract is ahead of schedule
• Fuel strategy looks more practical than many advanced-nuclear peers because Framatome's design uses standard LEU, reducing dependence on constrained HALEU supply
• The stock already reflects severe de-risking of expectations, trading 33.4% below its 200-day average and 85.9% below the 52-week high, so any signed TVA or Romania milestone could move the equity sharply

Bear Case

• The income statement remains effectively pre-commercial: FY2025 operating margin was -265.2%, net margin -273.4%, and Q2 EBITDA was -$0.05B on $0.1M of revenue
• Management still has not provided explicit revenue, OpEx, EBITDA, or commercialization guidance, and now points to RoPower revenue next year, 2027, rather than near-term recognition
• Execution credibility is mixed to weak, with major EPS misses in 2025-11-06 (-1225.0%) and 2026-02-26 (-700.0%), despite repeated statements about near-term commercial progress
• Positioning is unstable, not supportive: short interest is 58.48% of shares by one data cut, or 76.1M shares on a 130M float in the deep-dive set, while options gamma is negative and zero-gamma sits at $8.32, near spot

Valuation & Price Target

Engine price target $7.67 (-5.4% vs current), High confidence.

• P/S Multiple: $0.23 (1% weight)
• Quality-adjusted: $8.11 (20% weight)

The rating stays aligned with the quant baseline of HOLD and the high-confidence price target of $7.67, because the fundamental split is real: strategic assets and liquidity are strong, but current operating evidence is weak. A divergence to BUY would require either valuation support from a much lower price or a signed contract that makes 2027 revenue tangible; neither exists today. The peer-based valuation signal is noisy, with 8 peers, average P/E 21.1, and wide dispersion of 25.3x, while SMR itself has negative EPS and P/S 128.96x, so the most defensible stance is still to wait for proof. Street consensus is also Hold, but that is only passing context, not the basis for the call.

Risk Assessment

Risk score 56/100 (Moderate). The biggest risk is that definitive agreements slip again, because with quarterly revenue at just $0.1M and no formal financial guidance, even a strong $1.9B cash balance cannot justify a $2.5B equity value indefinitely.

The Bottom Line

SMR rates HOLD with High conviction. The balance sheet is strong enough to keep the story alive, and the regulatory and supply-chain position is better than many advanced nuclear peers. But the stock still lacks the one thing that turns optionality into investable cash flow: a signed, financeable customer commitment with visible revenue timing. A move to BUY would require either a materially lower entry price or definitive contract evidence from TVA or Romania. A move to SELL would require deterioration in liquidity or another clear pushout in commercial timing without offsetting contract wins.